A new position statement, jointly issued by seven international and European organizations, provides new guidance for the management of a...
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.
- Citation data:
Journal of bone oncology, ISSN: 2212-1366, Vol: 7, Page: 1-12
- Publication Year:
- Repository URL:
- Medicine; Oncology
- Most Recent Tweet View All Tweets
- Most Recent News Mention
Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase inhibitor (AI) therapy. Recently, a number of studies on additional fracture related risk factors, new treatment options as well as real world studies demonstrating a much higher fracture rate than suggested by randomized clinical controlled trials (RCTs). Therefore, this updated algorithm was developed to better assess fracture risk and direct treatment as a position statement of several interdisciplinary cancer and bone societies involved in the management of AI-associated bone loss (AIBL).